Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Characterization of Household and Community Shedding and Transmission of Oral Polio Vaccine in Mexican Communities With Varying Vaccination Coverage.

Altamirano J, Purington N, Behl R, Sarnquist C, Holubar M, García-García L, Ferreyra-Reyes L, Montero-Campos R, Cruz-Hervert LP, Boyle S, Modlin J, van Hoorebeke C, Leary S, Huang C, Sommer M, Ferreira-Guerrero E, Delgado-Sanchez G, Canizales-Quintero S, Díaz Ortega JL, Desai M, Maldonado YA.

Clin Infect Dis. 2018 Oct 30;67(suppl_1):S4-S17. doi: 10.1093/cid/ciy650.

2.

Protocol Paper: Oral Poliovirus Vaccine Transmissibility in Communities After Cessation of Routine Oral Poliovirus Vaccine Immunization.

Sarnquist C, Holubar M, García-García L, Ferreyra-Reyes L, Delgado-Sánchez G, Cruz-Hervert LP, Montero-Campos R, Altamirano J, Purington N, Boyle S, Modlin J, Ferreira-Guerrero E, Canizales-Quintero S, Díaz Ortega JL, Desai M, Maldonado YA.

Clin Infect Dis. 2018 Oct 30;67(suppl_1):S115-S120. doi: 10.1093/cid/ciy606.

3.

Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review.

Bandyopadhyay AS, Modlin JF, Wenger J, Gast C.

Clin Infect Dis. 2018 Oct 30;67(suppl_1):S35-S41. doi: 10.1093/cid/ciy633.

4.

Financial impact from in-office dispensing of oral chemotherapy.

Howard A, Kerr J, McLain M, Modlin J.

J Oncol Pharm Pract. 2018 Sep 24:1078155218799853. doi: 10.1177/1078155218799853. [Epub ahead of print]

PMID:
30249154
5.

Drug interaction screening in SWOG clinical trials.

Hertz DL, Siden R, Modlin J, Gabel LL, Wong SF.

Am J Health Syst Pharm. 2018 May 15;75(10):607-612. doi: 10.2146/ajhp170449.

PMID:
29748299
6.

Exploring the relationship between polio type 2 serum neutralizing antibodies and intestinal immunity using data from two randomized controlled trials of new bOPV-IPV immunization schedules.

Bandyopadhyay AS, Asturias EJ, O'Ryan M, Oberste MS, Weldon W, Clemens R, Rüttimann R, Modlin JF, Gast C.

Vaccine. 2017 Dec 19;35(52):7283-7291. doi: 10.1016/j.vaccine.2017.11.006. Epub 2017 Nov 14.

7.

Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study.

Taniuchi M, Famulare M, Zaman K, Uddin MJ, Upfill-Brown AM, Ahmed T, Saha P, Haque R, Bandyopadhyay AS, Modlin JF, Platts-Mills JA, Houpt ER, Yunus M, Petri WA Jr.

Lancet Infect Dis. 2017 Oct;17(10):1069-1079. doi: 10.1016/S1473-3099(17)30358-4. Epub 2017 Jul 7.

8.

The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.

Cavallari LH, Beitelshees AL, Blake KV, Dressler LG, Duarte JD, Elsey A, Eichmeyer JN, Empey PE, Franciosi JP, Hicks JK, Holmes AM, Jeng L, Lee CR, Lima JJ, Limdi NA, Modlin J, Obeng AO, Petry N, Pratt VM, Skaar TC, Tuteja S, Voora D, Wagner M, Weitzel KW, Wilke RA, Peterson JF, Johnson JA.

Clin Transl Sci. 2017 May;10(3):143-146. doi: 10.1111/cts.12456. Epub 2017 Mar 14. Review. No abstract available.

9.

Completing Polio Eradication: The Case for Antiviral Drugs.

Sutter RW, Modlin JF, Zaffran M.

J Infect Dis. 2017 Feb 1;215(3):333-334. doi: 10.1093/infdis/jiw547. No abstract available.

PMID:
27932609
10.

The enterovirus D68 epidemic.

Modlin JF.

Lancet Respir Med. 2015 Nov;3(11):829-30. doi: 10.1016/S2213-2600(15)00411-7. Epub 2015 Oct 5. No abstract available.

PMID:
26482319
11.

Treatment of Neonatal Enterovirus Infections.

Modlin JF.

J Pediatric Infect Dis Soc. 2016 Mar;5(1):63-4. doi: 10.1093/jpids/piv030. Epub 2015 May 18. No abstract available.

PMID:
26407264
12.

Achieving and maintaining polio eradication--new strategies.

Modlin J, Wenger J.

N Engl J Med. 2014 Oct 16;371(16):1476-9. doi: 10.1056/NEJMp1407783. No abstract available.

13.

Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication.

McKinlay MA, Collett MS, Hincks JR, Oberste MS, Pallansch MA, Okayasu H, Sutter RW, Modlin JF, Dowdle WR.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S447-53. doi: 10.1093/infdis/jiu043. Review.

PMID:
25316866
14.

Atypical hand, foot, and mouth disease: a vesiculobullous eruption caused by Coxsackie virus A6.

Feder HM Jr, Bennett N, Modlin JF.

Lancet Infect Dis. 2014 Jan;14(1):83-86. doi: 10.1016/S1473-3099(13)70264-0. Epub 2013 Nov 25.

PMID:
24287184
15.

Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs.

Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SG, Cochi SL, Kim JH, Thompson KM.

Risk Anal. 2013 Apr;33(4):606-46. doi: 10.1111/risa.12031. Epub 2013 Mar 28. Review.

PMID:
23550968
16.

Expert review on poliovirus immunity and transmission.

Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SG, Cochi SL, Kim JH, Thompson KM.

Risk Anal. 2013 Apr;33(4):544-605. doi: 10.1111/j.1539-6924.2012.01864.x. Epub 2012 Jul 15. Review.

PMID:
22804479
17.

Inactivated polio vaccine and global polio eradication.

Modlin JF.

Lancet Infect Dis. 2012 Feb;12(2):93-4. doi: 10.1016/S1473-3099(11)70312-7. Epub 2011 Nov 7. No abstract available.

PMID:
22071250
18.

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?

Watts NB, Roux C, Modlin JF, Brown JP, Daniels A, Jackson S, Smith S, Zack DJ, Zhou L, Grauer A, Ferrari S.

Osteoporos Int. 2012 Jan;23(1):327-37. doi: 10.1007/s00198-011-1755-2. Epub 2011 Sep 3.

19.

A fatal central nervous system enterovirus 68 infection.

Kreuter JD, Barnes A, McCarthy JE, Schwartzman JD, Oberste MS, Rhodes CH, Modlin JF, Wright PF.

Arch Pathol Lab Med. 2011 Jun;135(6):793-6. doi: 10.1043/2010-0174-CR.1.

PMID:
21631275
20.

The bumpy road to polio eradication.

Modlin JF.

N Engl J Med. 2010 Jun 24;362(25):2346-9. doi: 10.1056/NEJMp1005405. No abstract available.

21.

When to consider the use of antibiotics in the treatment of 2009 H1N1 influenza-associated pneumonia.

Wright PF, Kirkland KB, Modlin JF.

N Engl J Med. 2009 Dec 10;361(24):e112. doi: 10.1056/NEJMopv0910749. No abstract available.

22.

Empiric antibiotics are justified for infants with respiratory syncytial virus lower respiratory tract infection presenting with respiratory failure: a prospective study and evidence review.

Levin D, Tribuzio M, Green-Wrzesinki T, Ames B, Radwan S, Jarvis JD, Vaccaro T, Modlin JF.

Pediatr Crit Care Med. 2010 May;11(3):390-5. doi: 10.1097/PCC.0b013e3181b809c5.

PMID:
19838143
23.

Future of polio vaccines.

Ehrenfeld E, Modlin J, Chumakov K.

Expert Rev Vaccines. 2009 Jul;8(7):899-905. doi: 10.1586/erv.09.49. Review.

24.

A case for developing antiviral drugs against polio.

Collett MS, Neyts J, Modlin JF.

Antiviral Res. 2008 Sep;79(3):179-87. doi: 10.1016/j.antiviral.2008.04.002. Epub 2008 May 13. Review.

PMID:
18513807
25.

Immunisation against poliomyelitis: moving forward.

Ehrenfeld E, Glass RI, Agol VI, Chumakov K, Dowdle W, John TJ, Katz SL, Miller M, Breman JG, Modlin J, Wright P.

Lancet. 2008 Apr 19;371(9621):1385-7. doi: 10.1016/S0140-6736(08)60597-8. No abstract available.

PMID:
18424327
26.

A process for sentinel case review to assess causal relationships between smallpox vaccination and adverse outcomes, 2003-2004.

Chapman LE, Iskander JK, Chen RT, Neff J, Birkhead GS, Poland G, Gray GC, Siegel J, Sepkowitz K, Robertson RM, Yancy C, Guerra FA, Gardner P, Modlin JF, Maurer T, Berger T, Flanders WD, Shope R.

Clin Infect Dis. 2008 Mar 15;46 Suppl 3:S271-93. doi: 10.1086/524750.

PMID:
18284368
27.

Monitoring the safety of a smallpox vaccination program in the United States: report of the joint Smallpox Vaccine Safety Working Group of the advisory committee on immunization practices and the Armed Forces Epidemiological Board.

Neff J, Modlin J, Birkhead GS, Poland G, Robertson RM, Sepkowitz K, Yancy C, Gardner P, Gray GC, Maurer T, Siegel J, Guerra FA, Berger T, Flanders WD, Shope R; Advisory Committee on Immunization Practices; Armed Forces Epidemiological Board.

Clin Infect Dis. 2008 Mar 15;46 Suppl 3:S258-70. doi: 10.1086/524749.

PMID:
18284367
28.

The demise and rebirth of polio--a modern phoenix?

Wright PF, Modlin JF.

J Infect Dis. 2008 Feb 1;197(3):335-6. doi: 10.1086/525050. No abstract available.

PMID:
18199032
29.

Congenital rubella syndrome in a child born to Liberian refugees: clinical and public health perspectives.

Plotinsky RN, Talbot EA, Kellenberg JE, Reef SE, Buseman SK, Wright KD, Modlin JF.

Clin Pediatr (Phila). 2007 May;46(4):349-55.

PMID:
17475995
30.

Enterovirus déjà vu.

Modlin JF.

N Engl J Med. 2007 Mar 22;356(12):1204-5. No abstract available.

PMID:
17377157
31.

Decision analysis in planning for a polio outbreak in the United States.

Jenkins PC, Modlin JF.

Pediatrics. 2006 Aug;118(2):611-8.

PMID:
16882814
32.

Excretion of oral poliovirus vaccine strains: effect of vaccination schedule.

Modlin JF, Halsey NA.

J Infect Dis. 2006 Jun 1;193(11):1614-5. No abstract available.

PMID:
16652299
33.

Ensuring preparedness for potential poliomyelitis outbreaks: Recommendations for the US poliovirus vaccine stockpile from the National Vaccine Advisory Committee (NVAC) and the Advisory Committee on Immunization Practices (ACIP).

Alexander L, Birkhead G, Guerra F, Helms C, Hinman A, Katz S, LeBaron CW, Modlin J, Murphy TV; National Vaccine Advisory Committee-Advisory Committee on Immunization Practices Joint Working Group; Centers for Disease Control and Prevention.

Arch Pediatr Adolesc Med. 2004 Dec;158(12):1106-12. Review.

PMID:
15583093
34.

Poliomyelitis in the United States: the final chapter?

Modlin JF.

JAMA. 2004 Oct 13;292(14):1749-51. No abstract available.

PMID:
15479943
35.

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 25-2003. A newborn boy with petechiae and thrombocytopenia.

Modlin JF, Grant PE, Makar RS, Roberts DJ, Krishnamoorthy KS.

N Engl J Med. 2003 Aug 14;349(7):691-700. No abstract available.

PMID:
12917307
36.

A mass smallpox vaccination campaign: reasonable or irresponsible?

Modlin JF.

Eff Clin Pract. 2002 Mar-Apr;5(2):98-9. No abstract available.

PMID:
11990219
37.

American Pediatric Society John Howland Award 2000: presentation.

Modlin JF.

Pediatr Res. 2001 May;49(5):723-4. No abstract available.

PMID:
11328959
38.

Influenza vaccine for healthy working adults.

Chu SY, Singleton JA, McCauley MM, Orenstein WA, Hughes JM, Mawle AC, Modlin JF.

JAMA. 2001 Jan 17;285(3):291-2. No abstract available.

PMID:
11176835
39.

The coxsackie-adenovirus receptor (CAR) is used by reference strains and clinical isolates representing all six serotypes of coxsackievirus group B and by swine vesicular disease virus.

Martino TA, Petric M, Weingartl H, Bergelson JM, Opavsky MA, Richardson CD, Modlin JF, Finberg RW, Kain KC, Willis N, Gauntt CJ, Liu PP.

Virology. 2000 May 25;271(1):99-108.

40.

Clinical significance of enteroviruses in serious summer febrile illnesses of children.

Rotbart HA, McCracken GH Jr, Whitley RJ, Modlin JF, Cascino M, Shah S, Blum D.

Pediatr Infect Dis J. 1999 Oct;18(10):869-74.

PMID:
10530582
41.

Randomised trial of intradermal Mycobacterium vaccae or intradermal hepatitis B immunisation in children with HIV infection.

Johnson D, Waddell RD, Pelton SI, Jaeger AS, Modlin JF, Yogev R, Morin P, Arbeit RD, von Reyn CF.

Vaccine. 1999 Jun 4;17(20-21):2583-7.

PMID:
10418906
42.
43.

Surgical aspects of an outbreak of Yersinia enterocolitis.

Shorter NA, Thompson MD, Mooney DP, Modlin JF.

Pediatr Surg Int. 1998 Jan;13(1):2-5.

PMID:
9391192
44.

SCH 48973: a potent, broad-spectrum, antienterovirus compound.

Buontempo PJ, Cox S, Wright-Minogue J, DeMartino JL, Skelton AM, Ferrari E, Albin R, Rozhon EJ, Girijavallabhan V, Modlin JF, O'Connell JF.

Antimicrob Agents Chemother. 1997 Jun;41(6):1220-5.

45.

Immunization of healthy adult subjects in the United States with inactivated Mycobacterium vaccae administered in a three-dose series.

von Reyn CF, Arbeit RD, Yeaman G, Waddell RD, Marsh BJ, Morin P, Modlin JF, Remold HG.

Clin Infect Dis. 1997 May;24(5):843-8.

PMID:
9142780
46.

Diagnosis of enterovirus infection by polymerase chain reaction of multiple specimen types.

Rotbart HA, Ahmed A, Hickey S, Dagan R, McCracken GH Jr, Whitley RJ, Modlin JF, Cascino M, O'Connell JF, Menegus MA, Blum D.

Pediatr Infect Dis J. 1997 Apr;16(4):409-11. No abstract available.

PMID:
9109145
47.

Clinical coxsackievirus B isolates differ from laboratory strains in their interaction with two cell surface receptors.

Bergelson JM, Modlin JF, Wieland-Alter W, Cunningham JA, Crowell RL, Finberg RW.

J Infect Dis. 1997 Mar;175(3):697-700.

PMID:
9041347
49.

Group B coxsackie disease in children.

Modlin JF, Rotbart HA.

Curr Top Microbiol Immunol. 1997;223:53-80. Review. No abstract available.

PMID:
9294925
50.

Detection of enteroviruses by polymerase chain reaction in urine samples of patients with aseptic meningitis.

Nielsen LP, Modlin JF, Rotbart HA.

Pediatr Infect Dis J. 1996 Jul;15(7):625-7. No abstract available.

PMID:
8823859

Supplemental Content

Loading ...
Support Center